Cargando…

ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report

Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemura, Akira, Nitta, Hiroyuki, Sasaki, Akira, Takahara, Takeshi, Hasegawa, Yasushi, Wakabayashi, Go
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090435/
https://www.ncbi.nlm.nih.gov/pubmed/25045572
http://dx.doi.org/10.1155/2014/507621
_version_ 1782480628040597504
author Umemura, Akira
Nitta, Hiroyuki
Sasaki, Akira
Takahara, Takeshi
Hasegawa, Yasushi
Wakabayashi, Go
author_facet Umemura, Akira
Nitta, Hiroyuki
Sasaki, Akira
Takahara, Takeshi
Hasegawa, Yasushi
Wakabayashi, Go
author_sort Umemura, Akira
collection PubMed
description Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese woman with end stage LC-HCV, as a recipient, was preoperatively administered rituximab, mycophenolate mofetil, and steroids without plasma exchange. A routine ABO-I-LDLT procedure was applied using her daughter's HBc-Ab positive liver graft. Prophylaxis of the hepatitis B virus (HBV) infection using hepatitis B immunoglobulin (HBIG) and entecavir had been properly administered. Three months after the ABO-I-LDLT, HCV hepatitis relapsed. To date, this patient has been under antiviral therapy and prophylaxis of HBV infection using HBIG, while entecavir has been continued. The cognitions and techniques with regard to ABO-I-LDLT, prophylaxis of HBV cross infection, various patterns of immunosuppression, and antiviral therapy for HCV relapse are indispensable in managing a transplant recipient. According to the prophylaxis of HBV cross infection under ABO-I-LDLT, it may be very important to keep the HBs-Ab titer higher than usual for HBV naïve recipients, because severe systemic immunosuppression can cause de novo hepatitis.
format Online
Article
Text
id pubmed-4090435
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40904352014-07-20 ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report Umemura, Akira Nitta, Hiroyuki Sasaki, Akira Takahara, Takeshi Hasegawa, Yasushi Wakabayashi, Go Case Rep Transplant Case Report Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese woman with end stage LC-HCV, as a recipient, was preoperatively administered rituximab, mycophenolate mofetil, and steroids without plasma exchange. A routine ABO-I-LDLT procedure was applied using her daughter's HBc-Ab positive liver graft. Prophylaxis of the hepatitis B virus (HBV) infection using hepatitis B immunoglobulin (HBIG) and entecavir had been properly administered. Three months after the ABO-I-LDLT, HCV hepatitis relapsed. To date, this patient has been under antiviral therapy and prophylaxis of HBV infection using HBIG, while entecavir has been continued. The cognitions and techniques with regard to ABO-I-LDLT, prophylaxis of HBV cross infection, various patterns of immunosuppression, and antiviral therapy for HCV relapse are indispensable in managing a transplant recipient. According to the prophylaxis of HBV cross infection under ABO-I-LDLT, it may be very important to keep the HBs-Ab titer higher than usual for HBV naïve recipients, because severe systemic immunosuppression can cause de novo hepatitis. Hindawi Publishing Corporation 2014 2014-06-22 /pmc/articles/PMC4090435/ /pubmed/25045572 http://dx.doi.org/10.1155/2014/507621 Text en Copyright © 2014 Akira Umemura et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Umemura, Akira
Nitta, Hiroyuki
Sasaki, Akira
Takahara, Takeshi
Hasegawa, Yasushi
Wakabayashi, Go
ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title_full ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title_fullStr ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title_full_unstemmed ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title_short ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
title_sort abo-incompatible living donor liver transplantation from hepatitis b core antibody positive donor to hepatitis c liver cirrhosis recipient: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090435/
https://www.ncbi.nlm.nih.gov/pubmed/25045572
http://dx.doi.org/10.1155/2014/507621
work_keys_str_mv AT umemuraakira aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport
AT nittahiroyuki aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport
AT sasakiakira aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport
AT takaharatakeshi aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport
AT hasegawayasushi aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport
AT wakabayashigo aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport